Arginetix raises $10.75 million
This article was originally published in Scrip
Executive Summary
Arginetix, a Baltimore-based company developing small-molecule inhibitors of the enzyme arginase, has raised $10.75 million in an initial financing led by MedImmune Ventures and Quaker BioVentures.